The HemOnc Pulse

Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma

Mar 9, 2023

35:20

Creator website

Highlights

AI Chapters

Episode notes

Checkpoint Inhibitors in Hodgkin Lymphoma

02:03

Is CAR-T Cell a Relapsed Hodgkin Lymphoma?

01:56

Relapsed GVD - What's Next?

02:16

Introduction

2min

Hodgkin Lymphoma at Ash - What's the Latest Big Trial?

4min

Is Bleamycin a Good Treatment for ABVD?

3min

ABVD Brintoxinab

2min

Is AAVD Brintoxinab for Neuropathy?

4min

Relapsed GVD - What's Next?

2min

Checkpoint Inhibitors in Hodgkin Lymphoma

2min

Nivo ICE - Phase Two Single Arm Study?

2min

Is NICE Better Than Ice?

2min

10.

PD One Inhibitor

2min

11.

Is CAR-T Cell a Relapsed Hodgkin Lymphoma?

2min

12.

Early Stage Hodgkin Disease - Is There a Future?

3min

13.

The Advanced Stage Hodgkin International Prognostic Index

3min

14.

Is There a Way Forward With Hodgkin's Chemotherapy?

3min

In the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre, discusses the findings from the HoLISTIC Consortium, and what he thinks about checkpoint inhibitors upfront in the treatment of Hodgkin lymphoma.